2. NF-κB Immunology/Inflammation
  3. NF-κB IKK COX Interleukin Related
  4. SR12343

SR12343 is a IKK/NF-κB inhibitor and a mimetic of the NF-κB essential modulator (NEMO)-binding domain (NBD). SR12343 inhibits TNF-α- and LPS-induced NF-κB activation by blocking the interaction between IKKβ and NEMO. SR12343 suppresses LPS-induced acute pulmonary inflammation in mice. SR12343 extends the healthspan of naturally aged and accelerated aging mice. SR12343 can be used for research on inflammatory and degenerative diseases.

For research use only. We do not sell to patients.

SR12343

SR12343 Chemical Structure

CAS No. : 2055101-86-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

SR12343 Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All IKK Isoform Specific Products:

View All Isoforms
IKK-α IKK-β IKK IKKε TBK1

View All COX Isoform Specific Products:

View All Isoforms
COX COX-1 COX-2 COX-3

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SR12343 is a IKK/NF-κB inhibitor and a mimetic of the NF-κB essential modulator (NEMO)-binding domain (NBD). SR12343 inhibits TNF-α- and LPS-induced NF-κB activation by blocking the interaction between IKKβ and NEMO. SR12343 suppresses LPS-induced acute pulmonary inflammation in mice. SR12343 extends the healthspan of naturally aged and accelerated aging mice. SR12343 can be used for research on inflammatory and degenerative diseases[1][2].

In Vitro

SR12343 (25-150 μM; 30 min) inhibits TNF-α-induced NF-κB activation in HEK293 cells in a dose-dependent manner, with an IC50 of 37.02 μM[2].
SR12343 (50 μM; 30 min) significantly inhibits the expression of COX-2, IL-6 and iNOS in Raw 264.7 macrophages induced by LPS (HY-D1056)[2].
SR12343 (25-50 μM; 1 h) inhibits LPS-induced IL-6 secretion in Raw 264.7 macrophages[2].
SR12343 (25-150 μM; 30 min) dose-dependently disrupts the interaction between endogenous NEMO and IKKβ in Raw 264.7 macrophages, while exerting minimal effect on the binding of NEMO and IKKα[2].
SR12343 (150 μM; 30 min) inhibits the activation of the canonical IKK/NF-κB pathway induced by TNF-α and LPS in Raw 264.7 macrophages, without affecting the JNK or p38MAPK signaling pathways[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SR12343 Related Antibodies

Real Time qPCR[2]

Cell Line: Raw 264.7 macrophages
Concentration: 50 μM
Incubation Time: 30 min
Result: Significantly inhibited LPS-induced expression of cyclooxygenase 2 (COX-2), interleukin-6 (IL-6), and inducible nitric oxide synthase (iNOS).
Did not significantly inhibit expression of IL-1β, TNF-α, or IκBα.

ELISA Assay[2]

Cell Line: Raw 264.7 macrophages
Concentration: 25 μM, 50 μM
Incubation Time: 1 h
Result: Reduced LPS-induced IL-6 secretion to ~1.2 ng/mL at 25 μM.
Reduced LPS-induced IL-6 secretion to ~1.4 ng/mL at 50 μM, compared to ~2.8 ng/mL in LPS-only controls.

Western Blot Analysis[2]

Cell Line: Raw 264.7 macrophages
Concentration: 150 μM
Incubation Time: 30 min
Result: Reduced TNF-α- and LPS-induced phosphorylation of IKKα/β, IκBα, and p65.
Partially reduced IκBα degradation.
Did not affect phosphorylation of JNK or p38MAPK.
Did not affect total levels of JNK, p38MAPK, IKKα, IKKβ, or p65.
In Vivo

SR12343 (10 mg/kg; i.p.; single dose) attenuates LPS-induced acute pulmonary inflammation in C57BL/6J mice by suppressing NF-κB target gene expression and reducing circulating IL-6 levels[2].
SR12343 (30 mg/kg; i.p.; 3 times per week; 4 weeks) improves muscular pathology, reduces inflammation and fibrosis, enhances muscle regeneration, and increases forelimb strength in mdx mice, a model of DMD, with no overt toxicity[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (female, 8-10 weeks old, 20-30 g, intraperitoneal injection of 10 mg/kg LPS (strain O111:B4) induced model)[2]
Dosage: 10 mg/kg
Administration: i.p.; single dose
Result: Significantly inhibited mRNA expression of iNOS, IκBα, COX-2, and IL-6 in lung tissue.
Significantly inhibited only COX-2 mRNA expression in liver tissue.
Reduced LPS-induced phosphorylation of IκBα and COX-2 expression in both lung and liver at the protein level.
Reduced serum IL-6 levels that increased significantly after LPS induction.
Slightly reduced white blood cell and neutrophil counts.
Animal Model: C57BL/10ScSn-Dmdmdx/J (sex-matched, 3 weeks old at study start, 7 weeks old at endpoint, spontaneous model)[2]
Dosage: 30 mg/kg
Administration: i.p.; 3 times per week; 4 weeks
Result: Significantly reduced the percentage of necrotic and inflammatory area in TA muscle by ~90% relative to vehicle controls.
Reduced muscle fibrosis by ~40% in diaphragm muscle and ~35% in TA muscle.
Reduced CD68+ macrophage infiltration by ~50% in both diaphragm and TA muscle.
Significantly increased mRNA expression of embryonic myosin heavy chain (eMyHC) and Pax7 in TA muscle relative to vehicle.
Reduced the Feret diameter of centrally nucleated and non-centrally nucleated myofibers in TA muscle.
Increased forelimb grip strength normalized to body weight significantly relative to vehicle controls at both 2 weeks and 4 weeks post-treatment start.
Caused no significant weight loss or liver toxicity (assessed by serum AST, ALT, ALP levels).
Reduced NF-κB DNA binding activity in TA muscle 2 hours post single 30 mg/kg dose injection.
Molecular Weight

368.66

Formula

C15H15BrClN3O
CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C(NCCC1=CC=CC(Br)=C1)CNC2=NC=C(Cl)C=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (271.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7125 mL 13.5626 mL 27.1253 mL
5 mM 0.5425 mL 2.7125 mL 5.4251 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.66%

SDS (251 KB)

COA (243 KB) HNMR (275 KB) LCMS (105 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.7125 mL 13.5626 mL 27.1253 mL 67.8132 mL
5 mM 0.5425 mL 2.7125 mL 5.4251 mL 13.5626 mL
10 mM 0.2713 mL 1.3563 mL 2.7125 mL 6.7813 mL
15 mM 0.1808 mL 0.9042 mL 1.8084 mL 4.5209 mL
20 mM 0.1356 mL 0.6781 mL 1.3563 mL 3.3907 mL
25 mM 0.1085 mL 0.5425 mL 1.0850 mL 2.7125 mL
30 mM 0.0904 mL 0.4521 mL 0.9042 mL 2.2604 mL
40 mM 0.0678 mL 0.3391 mL 0.6781 mL 1.6953 mL
50 mM 0.0543 mL 0.2713 mL 0.5425 mL 1.3563 mL
60 mM 0.0452 mL 0.2260 mL 0.4521 mL 1.1302 mL
80 mM 0.0339 mL 0.1695 mL 0.3391 mL 0.8477 mL
100 mM 0.0271 mL 0.1356 mL 0.2713 mL 0.6781 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SR12343 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SR123432055101-86-3SR 12343SR-12343NF-κBIKKCOXInterleukin RelatedNuclear factor-κBNuclear factor-kappaBIκB kinaseI kappa B kinase CyclooxygenaseILTNF-αmdx miceRaw 264.7 macrophagesHEK293 cellsC57BL/6J miceLPSsenescencesenescence-associated secretory phenotypeIKKβ-NEMO complexInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SR12343
Cat. No.:
HY-123936
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.